J
James B. Young
Researcher at Cleveland Clinic
Publications - 538
Citations - 46895
James B. Young is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Heart failure & Transplantation. The author has an hindex of 102, co-authored 517 publications receiving 43826 citations. Previous affiliations of James B. Young include Case Western Reserve University & Baylor University.
Papers
More filters
Journal ArticleDOI
Intracoronary thrombolytic therapy in acute myocardial infarction: a prospective, randomized, controlled trial.
Albert E. Raizner,Francisco A. Tortoledo,Mario S. Verani,Richard E. van Reet,James B. Young,Frank D. Rickman,W.Richard Cashion,David A. Samuels,Craig M. Pratt,Mohammed Attar,Howard S. Rubin,John M. Lewis,Milton S. Klein,Robert Roberts +13 more
TL;DR: A prospective, randomized trial was designed to assess the efficacy of intracoronary thrombolytic therapy with streptokinase (STK) in acute myocardial infarction and showed wide variability of response.
Journal ArticleDOI
Prinzmetal's angina during 5-fluorouracil chemotherapy.
TL;DR: Variant angina developed during intravenous 5-fluorouracil therapy in a patient without prior history of angina pectoris and was prevented by prophylactic calcium antagonist therapy.
Journal ArticleDOI
Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)
Gregg C. Fonarow,William T. Abraham,Nancy M. Albert,Wendy Gattis Stough,Wendy Gattis Stough,Mihai Gheorghiade,Barry H. Greenberg,Christopher M. O'Connor,Jie Lena Sun,Clyde W. Yancy,James B. Young +10 more
TL;DR: The doses of beta blockers applied in clinical practice are substantially less that the doses achieved in randomized clinical trials in HF and recommended in national guidelines, and little up-titration in beta-blocker dosing occurs in the first 60 to 90 days after hospital discharge.
Journal ArticleDOI
B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure.
James O. O'Neill,Corinne Bott-Silverman,Andrew T. Mcrae,Richard W. Troughton,Kenneth Ng,Randall C. Starling,James B. Young +6 more
TL;DR: In patients with severe heart failure, BNP levels do not accurately predict serial hemodynamic changes and do not obviate the need for pulmonary artery catheterization.
Journal ArticleDOI
Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging.
Samir R. Kapadia,Khaled M. Ziada,Philippe L. L’Allier,Tim Crowe,Gustavo Rincon,Robert E. Hobbs,Corinne Bott-Silverman,James B. Young,Steven E. Nissen,E. Murat Tuzcu +9 more
TL;DR: Multivessel imaging is more sensitive in detecting the transplant vasculopathy lesions compared to single-vessel imaging, and this important variable should be considered when designing and interpreting trials utilizing intravascular imaging derived end-point.